Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre <scp>UK</scp> experienceNicola Maciocia, Neil Rabin, Steve Schey et al.|British Journal of Haematology|2017Cited by 31
Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon StudyKwee Yong, Roger G. Owen, Rakesh Popat et al.|Blood|2019Cited by 8
Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK ExperienceNicola Maciocia, Neil Rabin, Andrew Melville et al.|Blood|2016Cited by 2
Real-World Mobilization, Harvest, and Transplant Outcomes in Newly Diagnosed Multiple Myeloma Patients Receiving D-VTd: A UK Centre ExperienceChristianne Bourlon, Stella Bouziana, Katharine Bailey et al.|Blood|2023Cited by 1